Abstrakt

Aim: Long-term studies show that some metabolic syndrome (MS) components deteriorate renal function in autosomal dominant polycystic kidney disease (ADPKD) patients. The aim of this 6-year follow-up was to analyze early changes of all MS components and their associations with kidney function in the nondiabetic ADPKD patients with normal renal function, compared to controls. Material/Methods: The follow-up physical and laboratory examinations were performed for 39 ADPKD patients (age 43.7 ± 11.4 years) and 44 controls (43.5 ± 9.1 years). Results: We noticed a significant increase in weight, body mass index (BMI), waist, total and LDL cholesterol, C-peptide, uric acid, creatinine and significant decline of HbA1c and e-GFR in the ADPKD group. Increases in waist, uric acid and creatinine concentrations were significantly higher in the ADPKD patients than controls. Both groups showed similar rates of prediabetes, while diabetes developed in 5 controls (with 4 cases of type 2 diabetes and one case of type 1), but not in the ADPKD group (11% vs 0%, P = 0.06 for diabetes, 9% vs 0%, P = 0.12 for type 2 diabetes). The ADPKD group showed a significantly higher percentage of obesity, waist circumferences, systolic/diastolic blood pressure, concentrations of creatinine, urea and uric acid and lower e-GFR. The MS prevalence was comparable; however, the number of MS components was significantly higher in the ADPKD patients (median 2 vs. 1, p = 0.001). Conclusions: The presence of MS does not influence the rate of renal failure progression in nondiabetic ADPKD patients with normal renal function at a 6-year follow-up.

Przypisy

• 1. Bansal R.K., Kapoor A.: Laparoscopic nephrectomy for massivepolycystic kidney disease: Updated technique and outcomes. Can.Urol. Assoc. J., 2014; 8: 341–345
  Google Scholar
• 2. Bayer N.D., Cochetti P.T., Anil Kumar M.S., Teal V., Huan Y., DoriaC., Bloom R.D., Rosas S.E.: Association of metabolic syndrome withdevelopment of new-onset diabetes after transplantation. Transplantation,2010; 90: 861–866
  Google Scholar
• 3. Chapman A.B., Guay-Woodford L.M., Grantham J.J., Torres V.E.,Bae K.T., Baumgarten D.A., Kenney P.J., King B.F. Jr., Glockner J.F.,Wetzel L.H., Brummer M.E., O’Neill W.C., Robbin M.L., Bennett W.M.,Klahr S., et al.: Consortium for Radiologic Imaging Studies of PolycysticKidney Disease cohort: Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium forRadiologic Imaging Studies of Polycystic Kidney Disease (CRISP)cohort. Kidney Int., 2003; 64: 1035–1045
  Google Scholar
• 4. Chen J., Muntner P., Hamm L.L., Jones D.W., Batuman V., FonsecaV., Whelton P.K., He J.: The metabolic syndrome and chronic kidneydisease in U.S. adults. Ann. Intern. Med., 2004; 140: 167–174
  Google Scholar
• 5. Cohen E., Nardi Y., Krause I., Goldberg E., Milo G., Garty M., KrauseI.: A longitudinal assessment of the natural rate of decline in renalfunction with age. J. Nephrol., 2014; 27: 635–641
  Google Scholar
• 6. Denic A., Glassock R.J., Rule A.D.: Structural and functional changeswith the aging kidney. Adv. Chronic Kidney Dis., 2016; 23: 19–28
  Google Scholar
• 7. Ecder T., Schrier R.W.: Hypertension in autosomal-dominant polycystickidney disease: early occurrence and unique aspects. J. Am.Soc. Nephrol., 2001; 12: 194–200
  Google Scholar
• 8. Expert Panel on Detection, Evaluation, and Treatment of HighBlood Cholesterol in Adults: Executive Summary of The Third Reportof The National Cholesterol Education Program (NCEP) Expert Panelon Detection, Evaluation, And Treatment of High Blood CholesterolIn Adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486–2497
  Google Scholar
• 9. Han M., Park H.C., Kim H., Jo H.A., Huh H., Jang J.Y., Kang A.Y.,Kim S.H., Cheong H.I., Kang D.H., Yang J., Oh K.H., Hwang Y.H.,Ahn C.: Hyperuricemia and deterioration of renal function inautosomal dominant polycystic kidney disease. BMC Nephrol.,2014; 15: 63
  Google Scholar
• 10. Helal I., McFann K., Reed B., Yan X.D., Schrier R.W., Fick-BrosnahanG.M.: Serum uric acid, kidney volume and progressionin autosomal-dominant polycystic kidney disease. Nephrol. Dial.Transplant., 2013; 28: 380–385
  Google Scholar
• 11. Higashihara E., Horie S., Muto S., Mochizuki T., Nishio S., NutaharaK.: Renal disease progression in autosomal dominant polycystic kidneydisease. Clin. Exp. Nephrol., 2012; 16: 622–628
  Google Scholar
• 12. Hogan M.C., Abebe K., Torres V.E., Chapman A.B., Bae K.T., TaoC., Sun H., Perrone R.D., Steinman T.I., Braun W., Winklhofer F.T.,Miskulin D.C., Rahbari-Oskoui F., Brosnahan G., Masoumi A., et al.:Liver involvementin early autosomal-dominant polycystic kidneydisease. Clin. Gastroenterol. Hepatol., 2015; 13: 155–164
  Google Scholar
• 13. Howard G., Safford M.M., Moy C.S., Howard V.J., Kleindorfer D.O.,Unverzagt F.W., Soliman E.Z., Flaherty M.L., McClure L.A., LacklandD.T., Wadley V.G., Pulley L., Cushman M.: Racial differences in theincidenceof cardiovascular risk factors in older black and whiteadults. J. Am. Geriatr. Soc., 2017; 65: 83–90
  Google Scholar
• 14. Hunsicker L.G., Adler S., Caggiula A., England B.K., Greene T.,Kusek J.W., Rogers N.L., Teschan P.E.: Predictors of the progressionof renal disease in the Modification of Diet in Renal Disease Study.Kidney Int., 1997; 51: 1908–1919
  Google Scholar
• 15. Joly D., Hummel A., Ruello A., Knebelmann B.: Ciliary functionof polycystins: a new model for cystogenesis. Nephrol. Dial. Transplant.,2003; 18: 1689–1692
  Google Scholar
• 16. Kawai K., Hayakawa H., Yoshida K., Shimizu M., Noto Y.: Plasmainsulin and C-peptide levels in cirrhotic and uremic patients. DiabeteMetab., 1977; 3: 7–10
  Google Scholar
• 17. Kelleher C.L., McFann K.K., Johnson A.M., Schrier R.W.:Characteristicsof hypertension in young adults with autosomaldominant polycystickidney disease compared with the general U.S.population. Am. J. Hypertens., 2004; 17: 1029–1034
  Google Scholar
• 18. Kimberling W.J., Kumar S., Gabow P.A., Kenyon J.B., ConnollyC.J., Somlo S.: Autosomal dominant polycystic kidney disease: localizationof the second gene to chromosome 4q13–q23. Genomics,1993; 18: 467–472
  Google Scholar
• 19. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F. 3rd,Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., CoreshJ., CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration):A new equation to estimate glomerular filtration rate. Ann. Intern.Med., 2009; 150: 604–612
  Google Scholar
• 20. Levy J.C., Matthews D.R., Hermans M.P.: Correct homeostasismodel assessment (HOMA) evaluation uses the computer program.Diabetes Care, 1998; 21: 2191–2192
  Google Scholar
• 21. Locatelli F., Pozzoni P., Del Vecchio L.: Renal manifestations inthe metabolic syndrome. J. Am. Soc. Nephrol., 2006; 17: S81–S85
  Google Scholar
• 22. Mao Z., Xie G., Ong A.C.: Metabolic abnormalities in autosomaldominant polycystic kidney disease. Nephrol. Dial. Transplant.,2015; 30: 197–203
  Google Scholar
• 23. Ozkok A., Akpinar T.S., Tufan F., Kanitez N.A., Uysal M., GuzelM., Caliskan Y., Alisir S., Yazici H., Ecder T.: Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience.Clin. Exp. Nephrol., 2013; 17: 345–351
  Google Scholar
• 24. Panizo N., Goicoechea M., García de Vinuesa S., Arroyo D., YusteC., Rincón A., Verdalles U., Ruiz-Caro C., Quiroga B., Luño J.: Chronickidney disease progression in patients with autosomal dominantpolycystic kidney disease. Nefrologia, 2012; 32: 197–205
  Google Scholar
• 25. Pei Y., Watnick T.: Diagnosis and screening of autosomal dominantpolycystic kidney disease. Adv. Chronic. Kidney Dis., 2010; 17: 140–152
  Google Scholar
• 26. Pietrzak-Nowacka M., Safranow K., Byra E., Bińczak-Kuleta A.,Ciechanowicz A., Ciechanowski K.: Metabolic syndrome componentsin patients with autosomal-dominant polycystic kidney disease.Kidney Blood Press. Res., 2009; 32: 405–410
  Google Scholar
• 27. Pietrzak-Nowacka M., Safranow K., Palacz J., Gołembiewska E.,Marchelek-Myśliwiec M., Ciechanowski K.: Association of kidney andcysts dimensions with anthropometric and biochemical parametersin patients with ADPKD. Ren. Fail., 2015; 37: 798–803
  Google Scholar
• 28. Ravine D., Gibson R.N., Walker R.G., Sheffield L.J., Kincaid-Smith P.,Danks D.M.: Evaluation of ultrasonographic diagnostic criteria for autosomaldominant polycystic kidney disease 1. Lancet, 1994; 343: 824–827
  Google Scholar
• 29. Reed B., Helal I., McFann K., Wang W., Yan X.D., Schrier R.W.:The impact of type II diabetes mellitus in patients with autosomaldominant polycystic kidney disease. Nephrol. Dial. Transplant.,2012; 27: 2862–2865
  Google Scholar
• 30. Reule S., Sexton D.J., Solid C.A., Chen S.C., Collins A.J., FoleyR.N.: ESRD from autosomal dominant polycystic kidney disease inthe United States, 2001-2010. Am. J. Kidney Dis., 2014; 64: 592–599
  Google Scholar
• 31. Rivera J.V., Martinez Maldonado M., Ramirezdearellano G.A.,Ehrlich L.: Association of hyperuricemia and polycystic kidney disease.Bol. Asoc. Med. P. R., 1965; 57: 251–262
  Google Scholar
• 32. Rowe I., Chiaravalli M., Mannella V., Ulisse V., Quilici G., PemaM., Song X.W., Xu H., Mari S., Qian F., Pei Y., Musco G., Boletta A.: Defectiveglucose metabolism in polycystic kidney disease identifies anew therapeutic strategy. Nat. Med., 2013; 19: 488–493
  Google Scholar
• 33. Rutkowski B., Lichodziejewska-Niemierko M., Grenda R.: Reporton the renal replacement therapy in Poland-2010. Drukonsul,Gdańsk, 2013
  Google Scholar
• 34. Schrier R.W., Abebe K.Z., Perrone R.D., Torres V.E., Braun W.E.,Steinman T.I., Winklhofer F.T., Brosnahan G., Czarnecki P.G., HoganM.C., Miskulin D.C., Rahbari-Oskoui F.F., Grantham J.J., Harris P.C.,Flessner M.F., et al.: Blood pressure in early autosomal dominantpolycystickidney disease. N. Engl. J. Med., 2014; 371: 2255–2266
  Google Scholar
• 35. Song X., Di Giovanni V., He N., Wang K., Ingram A., RosenblumN.D., Pei Y.: Systems biology of autosomal dominant polycystic kidneydisease (ADPKD): computational identification of gene expressionpathways and integrated regulatory networks. Hum. Mol. Genet.,2009; 18: 2328–2343
  Google Scholar
• 36. The European Polycystic Kidney Disease Consortium: The polycystickidney disease 1 gene encodes a 14 kb transcript and lieswithin a duplicated region on chromosome 16. Cell, 1994; 77: 881–894
  Google Scholar
• 37. The International Diabetes Federation (IDF): The IDF consensusworldwide definition of the metabolic syndrome. http://www.idf.org/ webdata/docs/metac_syndrome_def.pdf
  Google Scholar
• 38. Torres V.E., Grantham J.J., Chapman A.B., Mrug M., Bae K.T., KingB.F. Jr., Wetzel L.H., Martin D., Lockhart M.E., Bennett W.M., Moxey-Mims M., Abebe K.Z., Lin Y., Bost J.E.: Consortium for RadiologicImaging Studies of Polycystic Kidney Disease (CRISP): Potentiallymodifiable factors affecting the progression of autosomal dominantpolycystic kidney disease. Clin. J. Am. Soc. Nephrol., 2011; 6: 640–647
  Google Scholar
• 39. WHO: Definition, Diagnosis and Classification of Diabetes Mellitusand its Complications. Report of a WHO Consultation. Part 1.Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO; 1999 https://apps.who.int/iris/bitstream/handle/10665/66040/WHO_NCD_NCS_99.2.pdf?sequence=1&isAllowed=y
  Google Scholar

Pełna treść artykułu